Exscientia stock.
Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.
Current and historical shares outstanding count for Exscientia.Exscientia Plc (EXAI) Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Exscientia Plc today and set a price target of $14.00 . The company’s shares closed last Thursday at $5.04 ...Dec 1, 2023 · A high-level overview of Exscientia plc (EXAI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Exscientia PLC ( EXAI) has gained Monday morning, with the stock adding 3.08% in pre-market trading to 6.36. EXAI's short-term technical score of 56 indicates that the stock has traded more bullishly over the last month than 56% of stocks on the market. In the Biotechnology industry, which ranks 131 out of 146 industries, the stock ranks higher ...
Legal Name Exscientia Ltd. Stock Symbol NASDAQ:EXAI. Company Type For Profit. Contact Email [email protected]. Phone Number +44-1865-818941. Exscientia …Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom. EXAI - Exscientia Plc ADR - Stock screener for investors and traders, financial ...Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, before the open of U.S. markets. The Company will host a ...
OXFORD, U.K., September 20, 2023--Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug ...OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A 2A receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, …
Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most ...Nov 2, 2023 · Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective ... OXFORD, U.K., March 23, 2023 -- ( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI) Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for ...
The Exscientia plc stock price gained 1.15% on the last trading day (Friday, 1st Dec 2023), rising from $6.10 to $6.17. During the last trading day the stock fluctuated 5.73% from a day low at $5.93 to a day high of $6.27. The price has been going up and down for this period, and there has been a 3.35% gain for the last 2 weeks.
PR Contacts: Edelman PR: Anitra Sprauten P: +44 (0)78 9685 9386 [email protected] Stephanie Crisp P: +44 (0)75 8300 3417 [email protected] For Exscientia Mark Swindells, Chief ...
10.10%. EXAI | A complete EXAI overview by MarketWatch. View the latest market news and prices, and trading information.Exscientia plc : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: EXAI | NasdaqNov 7, 2023 · Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 7.04% so far this month. During the month of November, Exscientia PLC (ADR)’s stock price has reached a high of $6.10 and a low of $5.15. Over the last year, Exscientia PLC (ADR) has hit prices as high as $11.52 and as low as $4.09. Year to date ... Apr 12, 2022 · This results in a target price of $34.4 (12.74 x 2.7) based on the current share price. This is a high target in view of current market conditions where stocks with negative earnings are being ... Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 5.38% so far this month. During the month of March, Exscientia PLC (ADR)’s stock price has reached a high of $7.11 and a low of $6.02. Over the last year, Exscientia PLC (ADR) has hit prices as high as $17.66 and as low as $4.09. Year to date, Exscientia ...
2012. 481. Andrew Hopkins. https://www.exscientia.ai. Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and ...Nov 29, 2023 · Stock analysis for Exscientia Plc (EXAI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 6 июл. 2023 г. ... In October 2021, Exscientia was floated on the Nasdaq stock market, raising $510 million, the largest initial public offering for a European ...Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 7.78% so far this month. During the month of November, Exscientia PLC (ADR)’s stock price has reached a high of $6.32 and a low of $4.95. Over the last year, Exscientia PLC (ADR) has hit prices as high as $11.52 and as low as $4.09. Year to date ...AUTL. Autolus Therapeutics PLC. 4.80. UNCH. UNCH. Get Exscientia PLC (EXAI:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.
Exscientia is a unique developmental concern using artificial intelligence to help identify promising drug compounds. ... The stock currently trades under $13.00 a share and sport a market ...Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 7.04% so far this month. During the month of November, Exscientia PLC (ADR)’s stock price has reached a high of $6.10 and a low of $5.15. Over the last year, Exscientia PLC (ADR) has hit prices as high as $11.52 and as low as $4.09. Year to date ...
Exscientia has raised a total of. $374.4M. in funding over 8 rounds. Their latest funding was raised on Jul 8, 2021 from a Grant round. Exscientia is registered under the ticker NASDAQ:EXAI . Their stock opened with $22.00 in its Oct 1, 2021 IPO. Exscientia is funded by 17 investors. Bill & Melinda Gates Foundation and Hongyou Investment are ...View the latest Exscientia PLC ADR (EXAI) stock price, news, historical charts, analyst ratings and financial information from WSJ. May 24, 2023 · That made the stock quite an outlier, as the S&P 500 index slipped by 0.7% on the day. So what Exscientia, which harnesses AI in the discovery and development of pharmaceuticals, published its ... Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar? finance.yahoo.com - October 12 at 9:54 AM: Exscientia plc (NASDAQ:EXAI) most popular amongst individual investors who own 58% of the shares, institutions hold 27% finance.yahoo.com - October 11 at 8:42 AMGreen's #1 AI Stock Summary. Creator: Alexander Green. Newsletter: Oxford Communique. Stock: Exscientia (EXIA) The stock that is being hyped up by Alexander Green is Exscientia. Exscientia is a company specializing in leveraging artificial intelligence for drug discovery, with a focus on designing and developing small-molecule drugs. OXFORD, England, March 14, 2023--Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ...Currently, the most bullish analyst values Exscientia at UK£13.35 per share, while the most bearish prices it at UK£9.43. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.Jun 15, 2021 · Exscientia, based in Oxford, England, is paying 50 million euros ($60.6 million) in a combination of cash and shares for the Vienna-based Allcyte, according to a company press release. You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.A. Exscientia ( EXAI) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 9, 2023 for Q3 and the Actual Revenue was $10.8M, which ...
Dec 1, 2023 · The Exscientia plc stock price gained 1.15% on the last trading day (Friday, 1st Dec 2023), rising from $6.10 to $6.17. During the last trading day the stock fluctuated 5.73% from a day low at $5.93 to a day high of $6.27. The price has been going up and down for this period, and there has been a 3.35% gain for the last 2 weeks.
Date Filing Type Filing Description Download / View. November 9, 2023. 6-K. Report of Foreign Issuer. September 20, 2023. 6-K. Report of Foreign Issuer. August 10, 2023. 6-K.
Legal Name Exscientia Ltd. Stock Symbol NASDAQ:EXAI. Company Type For Profit. Contact Email [email protected]. Phone Number +44-1865-818941. Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design ...According to the issued ratings of 3 analysts in the last year, the consensus rating for Exscientia stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for EXAI. The average twelve-month price prediction for Exscientia is $10.25 with a high price target of $13.00 and a low price target of $7.00.What is Exscientia's stock price target for 2024? 3 brokers have issued twelve-month price targets for Exscientia's shares. Their EXAI share price targets range from $7.00 to $13.00. On average, they predict the company's share price to reach $10.25 in the next year. This suggests a possible upside of 75.5% from the stock's current price.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comSep 20, 2023 · Exscientia will receive an upfront payment of $20 million in cash and be eligible for milestone payments of up to $674 million in total. If a drug is commercialized, the company will also receive ... Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.Of the 55 institutional investors that purchased Exscientia stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Novo Holdings A S ($13.09M), SB Global …According to 3 stock analysts, the average 12-month stock price forecast for Exscientia stock is $10, which predicts an increase of 62.07%. The lowest target is $7.00 and the highest is $13. On average, analysts rate Exscientia stock as a buy.
PARIS, OXFORD, and BOSTON – January 7, 2022 – Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule ...Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 7.78% so far this month. During the month of November, Exscientia PLC (ADR)’s stock price has reached a high of $6.32 and a low of $4.95. Over the last year, Exscientia PLC (ADR) has hit prices as high as $11.52 and as low as $4.09. Year to date ...According to 3 stock analysts, the average 12-month stock price forecast for Exscientia stock is $10, which predicts an increase of 62.07%. The lowest target is $7.00 and the highest is $13. On average, analysts rate Exscientia stock as a buy.Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Instagram:https://instagram. capptvanguard short term inflation protected securities index fundcamping world stockstax changes for 2024 Revenue: Revenue for the three and nine months ended September 30, 2023 was $10.8 million and $21.6 million respectively, compared to $7.7 million and $24.9 million for the three and nine months ...If a therapeutic is commercialized, Exscientia will receive tiered royalties on product sales. The stock has lost 5.1% year to date through Tuesday, while the S&P 500 has gained 15.7%. -Tomi Kilgore mercedes maybach glssls life Currently, the most bullish analyst values Exscientia at UK£13.35 per share, while the most bearish prices it at UK£9.43. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view. personal finance articles Exscientia's existing partnerships include collaborations with Celgene, GSK, Roche, Sanofi and Evotec. ... This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the …In the last 3 months, 7 analysts have offered 12-month price targets for Exscientia. The company has an average price target of $12.86 with a high of $14.00 and a low of $7.00. Below is a summary ...Get the latest stock quote, price, volume, change, and historical data of Exscientia (NASDAQ:EXAI), a biotechnology company that develops AI-powered …